参考文献/References:
[1] Moon JH,Hyun MK,Lee JY,et al.Prevalence of thyroid nodules and their associated clinical parameters:a large-scale,multicenter-based health checkup study[J].Korean J Intern Med,2018,33(4):753-762.DOI:10.3904/kjim.2015.273.
[2] Guth S,Theune U,Aberle J,et al.Very high prevalence of thyroid nodules detected by high frequency(13 MHz)ultrasound examination[J].Eur J Clin Invest,2009,39(8):699-706.DOI:10.1111/j.1365-2362.2009.02162.x.
[3] 赖晓英,欧阳平,朱宏,等.甲状腺结节检出情况及影响因素:10年309 576例体检人群分析[J].南方医科大学学报,2020,40(2):268-273.DOI:10.12122/j.issn.1673-4254.2020.02.20.
[4] Shan Z,Chen L,Lian X,et al.Iodine status and prevalence of thyroid disorders after introduction of mandatory universal salt Iodization for 16 years in China:a cross-sectional study in 10 cities[J].Thyroid,2016,26(8):1125-1130.DOI:10.1089/thy.2015.0613.
[5] Dean DS,Gharib H.Epidemiology of thyroid nodules[J].Best Pract Res Clin Endocrinol Metab,2008,22(6):901-911.DOI:10.1016/j.beem.2008.09.019.
[6] 中华医学会内分泌学分会,中华医学会外科学分会内分泌学组,中国抗癌协会头颈肿瘤专业委员会,等.甲状腺结节和分化型甲状腺癌诊治指南[J].中华内分泌代谢杂志,2012,28(10):779-797.DOI:10.3760/cma.j.issn.1000-6699.2012.10.002.
[7] 中华人民共和国国家卫生健康委员会.甲状腺癌诊疗规范(2018年版)[J].中华普通外科学文献(电子版),2019,13(1):1-15.DOI:10.3877/cma.j.issn.1674-0793.2019.01.001.
[8] Ahn HS,Kim HJ,Welch HG.Korea's thyroid-cancer "epidemic"—screening and overdiagnosis[J].N Engl J Med,2014,371(19):1765-1767.DOI:10.1056/NEJMp1409841.
[9] Lee JH,Shin SW.Overdiagnosis and screening for thyroid cancer in Korea[J].Lancet,2014,384(9957):1848.DOI:10.1016/S0140-6736(14)62242-X.
[10] Hoffman RM.Clinical practice.Screening for prostate cancer[J].N Engl J Med,2011,365(21):2013-2019.DOI:10.1056/NEJMcp1103642.
[11] Davies L,Welch HG.Increasing incidence of thyroid cancer in the United States,1973-2002[J].JAMA,2006,295(18):2164-2167.DOI:10.1001/jama.295.18.2164.
[12] 史晓光,杨雯晴,滕卫平.甲状腺癌的“过度诊断”和“过度治疗”[J].中华内分泌代谢杂志,2016,32(6):443-447.DOI:10.3760/cma.j.issn.1000-6699.2016.06.002.
[13] Jin J,McHenry CR.Thyroid incidentaloma[J].Best Pract Res Clin Endocrinol Metab,2012,26(1):83-96.DOI:10.1016/j.beem.2011.06.004.
[14] Morris LG,Sikora AG,Tosteson TD,et al.The increasing incidence of thyroid cancer:the influence of access to care[J].Thyroid,2013,23(7):885-891.DOI:10.1089/thy.2013.0045.
[15] Sipos JA,Mazzaferri EL.Thyroid cancer epidemiology and prognostic variables[J].Clin Oncol(R Coll Radiol),2010,22(6):395-404.DOI:10.1016/j.clon.2010.05.004.
[16] Londero SC,Krogdahl A,Bastholt L,et al.Papillary thyroid microcarcinoma in Denmark 1996-2008:a national study of epidemiology and clinical significance[J].Thyroid,2013,23(9):1159-1164.DOI:10.1089/thy.2012.0595.
[17] Morris LG,Myssiorek D.Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer:a population-based analysis[J].Am J Surg,2010,200(4):454-461.DOI:10.1016/j.amjsurg.2009.11.008.
[18] Tronko MD,Saenko VA,Shpak VM,et al.Age distribution of childhood thyroid cancer patients in Ukraine after Chernobyl and in Fukushima after the TEPCO-Fukushima Daiichi NPP accident[J].Thyroid,2014,24(10):1547-1548.DOI:10.1089/thy.2014.0198.
[19] Cardis E,Kesminiene A,Ivanov V,et al.Risk of thyroid cancer after exposure to 131I in childhood[J].J Natl Cancer Inst,2005,97(10):724-732.DOI:10.1093/jnci/dji129.
[20] Ohira T,Takahashi H,Yasumura S,et al.Comparison of childhood thyroid cancer prevalence among 3 areas based on external radiation dose after the Fukushima Daiichi nuclear power plant accident:the Fukushima health management survey[J].Medicine(Baltimore),2016,95(35):e4472.DOI:10.1097/MD.0000000000004472.
[21] Haugen BR,Alexander EK,Bible KC,et al.2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer:The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J].Thyroid,2016,26(1):1-133.DOI:10.1089/thy.2015.0020.
[22] US Preventive Services Task Force; Bibbins-Domingo K,Grossman DC,Curry SJ,et al.Screening for thyroid cancer:US Preventive Services Task Force Recommendation Statement[J].JAMA,2017,317(18):1882-1887.DOI:10.1001/jama.2017.4011.
[23] 王萍萍,曹慧,韩晓婷,等.临床cN0期甲状腺微小乳头状癌中央区淋巴结转移危险因素分析及手术方式探讨[J].中华内分泌外科杂志,2015,9(01):6-8,16.DOI:10.3760/cma.j.issn.1674-6090.2015.01.003.
[24] 盖宝东,刘晶,陈桂秋,等.长春和上海地区居民甲状腺结节性质的对比分析[J].中华普通外科杂志,2005,20(2):95-96.DOI:10.3760/j.issn:1007-631X.2005.02.009.
[25] Oda H,Miyauchi A,Ito Y,et al.Incidences of unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance versus immediate surgery[J].Thyroid,2016,26(1):150-155.DOI:10.1089/thy.2015.0313.
[26] Brito JP,Ito Y,Miyauchi A,et al.A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma[J].Thyroid,2016,26(1):144-149.DOI:10.1089/thy.2015.0178.
[27] Ito Y,Miyauchi A,Kihara M,et al.Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation[J].Thyroid,2014,24(1):27-34.DOI:10.1089/thy.2013.0367.
[28] Rondeau G,Fish S,Hann LE,et al.Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression[J].Thyroid,2011,21(8):845-853.DOI:10.1089/thy.
[29] Kwon H,Oh HS,Kim M,et al.Active surveillance for patients with papillary thyroid microcarcinoma:a single center's experience in Korea[J].J Clin Endocrinol Metab,2017,102(6):1917-1925.DOI:10.1210/jc.2016-4026.
[30] Jeon MJ,Kim WG,Kwon H,et al.Clinical outcomes after delayed thyroid surgery in patients with papillary thyroid microcarcinoma[J].Eur J Endocrinol,2017,177(1):25-31.DOI:10.1530/EJE-17-0160.
[31] Haymart MR,Miller DC,Hawley ST.Active surveillance for low-risk cancers- a viable solution to overtreatment[J].N Engl J Med,2017,377(3):203-206.DOI:10.1056/NEJMp1703787.
[32] Ross DS,Burch HB,Cooper DS,et al.2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis[J].Thyroid,2016,26(10):1343-1421.DOI:10.1089/thy.2016.0229.
[33] 中国抗癌协会甲状腺癌专业委员会(CATO).甲状腺微小乳头状癌诊断与治疗中国专家共识(2016版)[J].中国肿瘤临床,2016,43(10):405-411.DOI:10.3969/j.issn.1000-8179.2016.10.001.
[34] 中国医师协会甲状腺肿瘤消融治疗技术专家组,中国抗癌协会甲状腺癌专业委员会,中国医师协会介入医师分会超声介入专业委员会,等.甲状腺良性结节、微小癌及颈部转移性淋巴结热消融治疗专家共识(2018版)[J].中国肿瘤,2018,27(10):768-773.DOI:10.11735/j.issn.1004-0242.2018.10.A006.
[35] Wang MH,Liu X,Wang Q,et al.Safety and efficacy of ultrasound-guided thermal ablation in treating T1aN0M0 and T1bN0M0 papillary thyroid carcinoma:a meta-analysis[J].Front Endocrinol(Lausanne),2022,13:952113.DOI:10.3389/fendo.2022.952113.
[36] Mauri G,Hegedüs L,Bandula S,et al.European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 Clinical Practice Guideline for the Use of Minimally Invasive Treatments in Malignant Thyroid Lesions[J].Eur Thyroid J,2021,10(3):185-197.DOI:10.1159/000516469.
[37] Lee MC,Kim MJ,Choi HS,et al.Postoperative thyroid-stimulating hormone levels did not affect recurrence after thyroid lobectomy in patients with papillary thyroid cancer[J].Endocrinol Metab(Seoul),2019,34(2):150-157.DOI:10.3803/EnM.2019.34.2.150.
[38] Auer J,Scheibner P,Mische T,et al.Subclinical hyperthyroidism as a risk factor for atrial fibrillation[J].Am Heart J,2001,142(5):838-842.DOI:10.1067/mhj.2001.119370.